Benign breast disease (BBD) is a broad category of diagnoses reported to convey a variable
degree of increased risk of developing breast cancer. A meta-analysis of the existing …

Background Most clinical breast changes in women are benign; in only 3% to 6% of cases
are they due to breast cancer. However, there is a lack of up-to-date, evidence-based …

The therapeutic options for patients with noninvasive or invasive breast cancer are complex
and varied. These NCCN Clinical Practice Guidelines for Breast Cancer include …

Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group of
neoplastic lesions in the breast ducts. The goal for management of DCIS is to prevent the …

Antiestrogens include agents such as tamoxifen, toremifene, raloxifene, and fulvestrant.
Currently, tamoxifen is the only drug approved for use in breast cancer chemoprevention …

About 50 percent of women have histologic evidence of some degree of fibrocystic changes
in the breast. This review article describes the spectrum of benign breast disorders …

The degree of normal fibroglandular tissue that enhances on breast MRI, known as
background parenchymal enhancement (BPE), was initially described as an incidental …

Current hormonal therapies have benefited millions of patients with breast cancer. Their
success, however, is often temporary and limited to a subset of patients whose tumors …

Background: Risk factors may differentially influence development of estrogen receptor (ER)–
positive vs–negative breast cancer. We examined associations with strong, prevalent risk …

Depending on their structure and context, SERMs differentially modify expression of multiple
genes whose transcription is regulated by activated ER. 2, 3 A SERM's geneand tissue …